Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference

* wall-street.cz is not responsible for the content in this press release. Galena Biopharma (GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer, will present a corporate update at the 20th Annual Future Leaders …

Continue reading ‘Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference’ »

Galena Biopharma spinout RXi Pharma raises $26M

* wall-street.cz is not responsible for the content in this press release. RXi Pharma, a biotech focused on the development and commercialization of therapeutics using RNA-targeted technologies, has secured $26 million in funding, according to federal documents. The Westbrough, Mass. company, which spun out of Galena Biopharma Inc. (Nasdaq:GALE), a biotechnology company focused on developing targeted cancer …

Continue reading ‘Galena Biopharma spinout RXi Pharma raises $26M’ »

Galena Biopharma licenses cancer pain drug Abstral

* wall-street.cz is not responsible for the content in this press release. Galena pays $10M upfront to license Abstral, a treatment for severe episodes of cancer pain Galena Biopharma Inc. said Monday it acquired the U.S. rights to a fast-acting drug designed to treat severe pain in cancer patients. Galena is acquiring a drug called …

Continue reading ‘Galena Biopharma licenses cancer pain drug Abstral’ »

Frost & Sullivan Applauds Galena Biopharma for its Breakthrough Breast Cancer Vaccine, NeuVax™

* wall-street.cz is not responsible for the content in this press release. Tue Mar 12, 2013 7:45am EDT, NeuVax(TM) NeuVax(TM) strives to prevent the recurrence of breast cancer and sets a new standardin the global breast cancer vaccines market Reuters, March 12, 2013 – Based on its recent analysis of the breast cancer vaccines market, Frost & …

Continue reading ‘Frost & Sullivan Applauds Galena Biopharma for its Breakthrough Breast Cancer Vaccine, NeuVax™’ »

NeuVax: About the PRESENT Trial

* wall-street.cz is not responsible for the content in this press release. NeuVax targets approximately 50-60% of HER2-positive patients (IHC 1+/2+ or FISH <2.2) who achieve remission with current standard of care treatment, but have no available HER2-targeted adjuvant treatment options to maintain their disease-free status.  Are you a breast cancer patient interested in participating …

Continue reading ‘NeuVax: About the PRESENT Trial’ »

USC Norris Comprehensive Cancer Center is enrolling women

* wall-street.cz is not responsible for the content in this press release. USC Norris Comprehensive Cancer Center is enrolling women with breast cancer in the NeuVax Ph. 3 PRESENT clinical trial Contact: Zeno Ashai 323-865-0463 zeno.ashai@med.usc.edu Trial 1B-12-3 “PRESENT”: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment. Type: Cancer …

Continue reading ‘USC Norris Comprehensive Cancer Center is enrolling women’ »

U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous

* wall-street.cz is not responsible for the content in this press release. A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ Biotechnology Index (IBB), the SPDR S&P Biotech ETF (XBI) and the First Trust Amex Biotechnology Index ETF (FBT) …

Continue reading ‘U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous’ »

Virginia Cancer Specialists recruiting

Virginia Cancer Specialists are recruiting breast cancer patients for the NeuVax PRESENT trial Clinical Research Trials Available Galena Biopharma PH3-01 “PRESENT” Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence Disease Types: Breast Available at: Arlington Office,  Fairfax Office,  Gainesville Office,  Loudoun Office,  Alexandria Office Principal Investigator: Nicholas J. Robert, M.D. For more information on this clinical trial, please …

Continue reading ‘Virginia Cancer Specialists recruiting’ »